Lyfgenia

lovotibeglogene autotemcel

Approval

ApplicationBLA 125788

Approval dateDec 8, 2023

Approval year2023

Sponsorbluebird bio, Inc

FDA-approved use

Treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events (VOEs). Production Information Package Insert - LYFGENIA Demographic Subgroup Information- LYFGENIA Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Lyfgenia:

"What was the basis for Lyfgenia's approval — what trials, what endpoints?"
"What adverse events did the FDA flag in the Lyfgenia medical review?"
"What regulatory pathway did Lyfgenia use — priority review, breakthrough, accelerated approval?"